At this year’s AANEM meeting in San Francisco, one clear message emerged: the treatment landscape for myasthenia gravis (MG) is advancing at remarkable speed, with the recent launch of Johnson & Johnson’s nipocalimab, and positive phase 3 results from Alexion Pharmaceuticals, Inc., Amgen Inc and Regeneron Medical.

Several key themes highlighted how this progress is reshaping both clinical and value frameworks in MG care:

• Shared decision-making as standard practice. There was growing consensus that treatment choice in MG should be a collaborative process — integrating clinical data with patients’ lived experiences, preferences, and treatment goals. This evolution reflects a broader shift toward partnership in chronic neurological care.
• Expanding definitions of value. Beyond clinical outcomes, attributes such as convenience, self-administration, and patient satisfaction are now recognized as legitimate drivers of product value. These factors not only improve adherence but also differentiate treatments within increasingly crowded therapeutic classes.
• Talks were suggestive of explorations of differentiation among FcRn blockers, underscoring that not all agents within a class are equal. Evidence of meaningful distinctions in delivery and real-world usability may drive differentiation.

Many at the meeting drew parallels between today’s MG environment and multiple sclerosis 15 years ago — a time when innovation, patient engagement, and new treatment modalities converged to transform outcomes. MG appears to be entering a similar era of accelerated progress, where the integration of clinical innovation, patient voice, and system readiness will define success.

The trajectory is clear: MG is transitioning from a rare, difficult-to-manage condition to a model for how science and patient-centered care can evolve together.

If you would like information on how Vitaccess Real MG, Vitaccess’ multi-client syndicated registry in MG, in partnership with the Myasthenia Gravis Foundation of America, Inc., could help with your evidence generation plans, please get in touch at info@vitaccess.com.